Australia, Dec. 23 -- Ultragenyx Pharmaceutical Inc., owns the trademark (2587929) for 'FAYUVI' till April 14, 2035.
Status: protected:
Registered/protected
Classes: 5 [Pharmaceutical preparations for the treatment of genetic, central nervous system, and lysosomal storage diseases and disorders; gene therapy products for the treatment of genetic, central nervous system, and lysosomal storage diseases and disorders, namely, virus vector-based gene therapy preparations for intravenous delivery.], 42 [Pharmaceutical, scientific, and medical research and development in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; scientific research in the nature of conducting clinical trials for others in the fi...